|
|
|
|
Therapy Eliminates Leukemia Stem Cells
New research describes a molecular tool that shows great promise as a therapeutic for human (AML), a notoriously treatment-resistant blood cancer.The study, published by Cell Press in the July 2nd issue of the journal Cell Stem Cell,...
|
|
|
BloodCenter develops new test to fight leukemia
A new test that can detect the genetic mutation linked to some types of acute myeloid leukemia is expected to help doctors tailor treatment for patients.The BloodCenter of Wisconsin has developed the test, called CEBPA...
|
|
|
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
John Koreth, MBBS, DPhil; Richard Schlenk, MD; Kenneth J.Kopecky, PhD; Sumihisa Honda, PhD; Jorge Sierra, MD, PhD; Benjamin J. Djulbegovic, MD, PhD; Martha Wadleigh, MD; Daniel J. DeAngelo, MD, PhD; Richard M. Stone, MD; Hisashi...
Journal of the American Medical Association:
Jun 26 2009 10:36AM
Matching: acute myeloid leukemia
|
Find similar documents
|
|
|
|
Dana Point family pulls together to battle cancer
Judy Brandmeier had gone to bed thinking about a fun wedding for her son at her Dana Point home.Just a month before Craig Brandmeier had proposed to his then girlfriend Katrina Armstrong in Las Vegas. When she hung up with her son that...
|
|
|
Characteristics of Intubated and Mechanically Ventilated Children in 16 Pediatric ICUs
Background When designing multicenter clinical trials it is important to understand the characteristics of children ventilated in pediatric ICUs (PICUs).Methods Secondary analysis of an existing data set of all intubated and...
|
|
|
New leukemia treatment shows promise
Acute myeloid leukemia is a challenging condition in elderly patients because conventional chemotherapy often causes severe side effects.A new drug called sapacitabine, which can be given orally, was tolerable and...
|
|
|
TopAbstracts in Angina Pectoris/MI 06/10/2009
TopAbstracts in Angina Pectoris/MI are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer...
|
|
|
Histamine Dihydrochloride/IL-2 Immunotherapy Maintains Improvement in Leukaemia-Free Survival in Acute Myeloid
my personal edition> leukaemias > news E-Mail this DGDispatch to a colleague DGDispatch BERLIN -- June 10, 2009 -- Immunotherapy with combined histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2) maintains its...
|
|
|
Stem cell transplants improve survival for some leukemia patients: study
Stem cell transplants improve survival among people with a common form of leukemia, researchers said Tuesday.Acute myeloid leukemia (AML) is the most common form of acute leukemia. It is usually treated...
|
|
|
Stem cell transplants improve survival for some leukemia patients: study
Stem cell transplants improve survival among people with a common form of leukemia, researchers said Tuesday.Acute myeloid leukemia (AML) is the most common form of acute leukemia. It is usually treated...
|
|
|
Stem cell transplants improve survival for some leukemia patients: study
Stem cell transplants improve survival among people with a common form of leukemia, researchers said Tuesday.Acute myeloid leukemia (AML) is the most common form of acute leukemia. It is usually treated...
|
|
|
Stem cell transplants improve survival among people with a common form of leukemia, researchers said Tuesday
Acute myeloid leukemia (AML) is the most common form of acute leukemia.It is usually treated with chemotherapy to produce a first remission, which nearly 70 per cent of patients under the age of 60 achieve,...
|
|
|
EpiCept's new data shows long-term durability of Ceplene in sustaining leukaemia-free survival
EpiCept Corporation has released new long-term data showing that the use of Ceplene when administered in conjunction with low-dose interleukin-2 (IL-2) provides durable protection from leukaemia relapse in patients with Acute ...
|
|
|
Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia
TUESDAY, June 9 (HealthDay News) -- For most patients with acute myeloid leukemia (AML) who come out of remission, donor stem cells appear to offer the best shot at survival, a new analysis shows.AML is the most common form of...
National Womens Health Information Center:
Jun 9 2009 9:38PM
Matching: acute myeloid leukemia
|
Find similar documents
|
|
|
|
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isofo
- Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented additional results from the ongoing...
|
|
|
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isofo
Partial Responses Demonstrated in 50 Percent of Evaluable Patients Treated in Phase 1 Trial Results Presented at the European Hematology Association Congress SEATTLE--(BUSINESS WIRE)--Jun 6, 2009 - Calistoga Pharmaceuticals, Inc., the leader...
|
|
|
Acute Myeloid Leukemia
_ Acute Myeloid Leukemia.
Journal of the American Medical Association:
Jun 9 2009 8:40PM
Matching: acute myeloid leukemia
|
Find similar documents
|
|
|
|
EpiCept Corporation to Present at the 5th Annual Noble Financial Equity Conference
- Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Jack Talley, President and CEO, will be presenting at the 5th Annual Noble Financial Equity Conference on Tuesday, June 9, 2009 at 8:40 a.m.
|
|
|
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isofo
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented additional results from the ongoing...
|
|
|
Sapacitabine Has Anti-Cancer Activity in Combination With
'We are encouraged by the wide spectrum of anti-cancer agents that result in synergy when combined with sapacitabine.The EHA data extend previously reported data and support clinical evaluation of sapacitabine given with various anti...
|
|
|
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isofo
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented additional results from the ongoing...
|
|
|
EpiCept Releases New Data Demonstrating Long-Term Durability Of Ceplene In Sustaining Leukemia-Free Survival
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) has released new long-term data showing that the use of Ceplene when administered in conjunction with low-dose interleukin-2 (IL-2) provides durable protection from leukemia...
|
|
|
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isofo
News source: Business Wire Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented additional...
|
|
|
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isofo
Partial Responses Demonstrated in 50 Percent of Evaluable Patients Treated in Phase 1 Trial Results Presented at the European Hematology Association Congress Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective...
|
|
|
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isofo
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented additional results from the ongoing...
|
